词条 | FCM (chemotherapy) | ||||||||||||||||||||
释义 |
FCM, or FMC in the context of chemotherapy is an acronym for a chemotherapy regimen that is often used in the treatment of indolent B cell non-Hodgkin's lymphomas. In combination with Rituximab this regimen is called R-FCM or R-FMC, or FCM-R, FMC-R. The [R]-FCM regimen contains
The FCM or R-FCM regimen is also sometimes used in some autoimmune diseases that are inherently sensitive to the use of rituximab, fludarabine, mitoxantrone, and cyclophosphamide alone in monotherapies (e.g., in severe multiple sclerosis flares). Dosing regimen{{unreferenced|section|date=January 2019}}
References1. ^http://www.bloodjournal.org/content/104/10/3064.full?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&volume=104&firstpage=3064&resourcetype=HWCIT&sso-checked=true The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group] 1 : Chemotherapy regimens used in lymphoma |
||||||||||||||||||||
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。